Market Overview

UPDATE: Bank Of America Reiterates On McKesson Ahead Of 4Q14 EPS

Related MCK
Who Will Feel The Pain From Generic Drug Price Inflation?
McKesson Launches Venture Fund, Appoints Tom Rodgers As Managing Director

In a report published Tuesday, Bank of America analyst Robert M. Willoughby reiterated an Underperform rating on McKesson (NYSE: MCK), and raised the price target from $160.00 to $165.00.

In the report, Bank of America noted, “Rebounding profitability in MCK's core drug wholesaling operations, traction for its ancillary franchises, and capital deployment initiatives should drive industry-leading earnings growth over a leaner infrastructure. However, at valuation highs following the announcement of its Celesio acquisition, we see more attractive investment opportunities elsewhere.”

McKesson closed on Monday at $174.23.

Latest Ratings for MCK

DateFirmActionFromTo
Oct 2014Deutsche BankMaintainsBuy
Oct 2014JP MorganMaintainsOverweight
Sep 2014BarclaysInitiates Coverage onOverweight

View More Analyst Ratings for MCK
View the Latest Analyst Ratings

Posted-In: Bank of America Robert M. WilloughbyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MCK)

Around the Web, We're Loving...

Get Benzinga's Newsletters